Global Non-Small Cell Lung Cancer Therapeutics Market – Snapshot

Non-small cell lung cancer therapeutics or NSCLC is one of the common forms of cancer treatments. This is due to the fact that NSCLC can metastasize in human bones, which can be a difficult for diagnose and treat the disease. In around 90% of the all types of lung cancer are of non-small cell lung cancer. Therapeutics for NSCLC first targets the cancer type from its first stage to its last. They are specifically designed from a blend of advanced proteins and simple chemistry. Increasing awareness because of several government initiatives are helping to boost the development of the global non-small cell lung cancer therapeutics market.

In addition to this, growing approvals for new drugs and non-small cell lung cancer therapeutics by the US FDA (Food and Drug Administration) and other authoritative bodies. Moreover, several other authoritative bodies are now funding several research and development activities and are thus lending their support for the development of the global non-small cell lung cancer therapeutics market.

A recent research report published by Transparency Market Research expects the global non-small cell lung cancer therapeutics market to exhibit a massive CAGR of 12.1% for the given forecast period of 2015 to 2023. This growth rate will take the market to a valuation worth US$15.1 bn by the end of 2023. Initially, the global non-small cell lung cancer therapeutics market was valued at US$4.9 bn in the year 2014.

Angiogenesis Inhibitor Segment to Show Most Growth Potential in Coming Years

In terms of pipeline, the global non-small cell lung cancer therapeutics market can be segmented in early stage (phase I and II) and late stage (phase III). In terms of class of drugs, the global market is further segmented into PD-1/PD-L1 inhibitor, kinase inhibitor, microtubule stabilizer, EGFR inhibitor, folate antimetabolites, and angiogenesis inhibitors. Of these, the segment of angiogenesis inhibitor is currently dominating the global market. This particular segment is projected to continue its domination in the global market for non-small cell lung cancer therapeutics over the course of the given period of assessment. The growth of the segment is mainly attributed to the increasing demand for highly effective and more targeted therapies in both established as well as emerging economies such as the US, India, Japan, and Europe among others. With such growing demand, the angiogenesis inhibitor segment of the non-small cell lung cancer therapeutics market is expected to exhibit a CAGR of 1.8% for the period of 2015 to 2023. With this growth rate, the segment is expected to reach a valuation worth US$2,020.4 mn by the fall of 2023.

Asia Pacific to Exhibit Promising Rate of Growth in Near Future

In terms of regional segmentation, the global non-small cell lung cancer therapeutics market has five major regions namely, North America, Latin America, Asia Pacific, Europe, and the Rest of the World. Among these, the regional segment of North America is currently dominating the international market because of the increasing support from the federal government in the US for enhancing the overall healthcare infrastructure. On the other hand, Asia Pacific segment is projected to show a promising rate of growth in the next few years of the forecast period. This growth is mainly attributed to the growing number of patient base suffering from lung cancer, increasing awareness about the availability of new treatment methods of cancer, and increasing spending on healthcare infrastructure in the emerging countries.

The vendor landscape of the global non-small cell lung cancer therapeutics market is a fragmented one because of the presence of numerous leading companies. Some of the most prominent brands in the global market are AstraZeneca Plc., Pfizer Inc., Eli Lilly and Company, Boehringer Ingelheim, Squibb, and Bristol Myers among others.

Of late, the demand for non-small cell lung cancer (NSCLC) therapeutics has witnessed a significant surge, globally. The robust rise in the number of patients suffering from NSCLC across the world is likely to strengthen this trend considerably in the near future. The market for NSCLC therapeutics presented a global opportunity worth US$4.9 bn in 2014. Analysts project it to rise at a CAGR of 12.10% during the period from 2015 to 2023 and attain a value of US$15.1 bn by the end of the forecast period. 

In this research report, the global NSCLC therapeutics market has been studied with a microscopic view. It aims at presenting a detailed market assessment on the basis of its past as well as current performance. The latest trends and growth opportunities within this market have been examined in-depth to determine its future status in this study. 

Non-Small Cell Lung Cancer Therapeutics Market: Trends and Opportunities 

Being the most common type of lung cancer, NSCLC has a large pool of patients suffering from it. Hitherto, angiogenesis inhibitor has been the most successful therapy for NSCLC. The high demand for Avastin in the U.S. and in several European countries is likely to maintain the position of angiogenesis inhibitor as the key treatment for NSCLC in the years to come. 

Folate antimetabolites, EGFR inhibitors, and microtubule stabilizers are also expected to gain momentum in the global market over the next few years. In addition, the approval of late-stage pipeline products, such as necitumumab and onartuzumab, are likely to create new revenue streams for drugmakers in the near future. 

Non-small Cell Lung Cancer Therapeutics Market: Geographical Analysis 

On the basis of geography, the global market for NSCLC therapeutics has been segmented into Europe, Asia Pacific, North America, and the Rest of the World. Thanks to the presence of a state-of-art healthcare infrastructure, North America has emerged as the leading contributor to this market. With favorable insurance and reimbursement scenario, researchers expect this regional market to remain dominant in the forthcoming years. 

On the other hand, Asia Pacific is anticipated to offer the most promising opportunities for growth in the near future. The increasing incidence of NSCLC, coupled with unmet medical needs, is likely to make way for the adoption of NSCLC therapeutics at a higher rate. The rise in government initiatives to increase awareness regarding NSCLC among consumers in this region is also projected to propel the Asia Pacific market for NSCLC therapeutics substantially over the next few years. 

Companies Mentioned in the Research Report 

Owing to the presence of a large pool of players, the global market for non-small cell lung cancer therapeutics demonstrates a highly competitive and fragmented landscape. Genentech Inc., GlaxoSmithKline PLC, Pfizer Inc., Astra Zeneca PLC, Celgene Corp., Eli Lilly & Co., Boehringer Ingelheim, Sun Pharmaceutical Industries Ltd., and Bristol-Myers Squibb are some of the key players in this market across the world. 

Key Segments of Non-Small Cell Lung Cancer Therapeutics Market 

By Drug Class

  • Angiogenesis Inhibitor
    • Avastin (bevacizumab)
    • Cyramza (Ramucirumab)
  • Epidermal Growth Factor Receptor Blocker
    • Tarceva (erlotinib)
    • Gilotrif (afatinib)
    • Iressa (gefitinib)
  • Kinase Inhibitor
    • Xalkori (crizotinib)
    • Zykadia (ceritinib)
  • Microtubule Stabilizer
    • Abraxane (paclitaxel protein bound)
    • Docetaxel
  • Folate Antimetabolites
    • Alimta (pemetrexed)
  • PD-1/ PD-L1 Inhibitor
    • Opdivo (nivolumab)
    • Keytruda (pembrolizumab)

By Pipeline

  • Early Stage (Phase I and II)
  • Late Stage (Phase III)
  • Avelumab - Pfizer Inc.
  • MPDL3280A - Roche
  • MEDI4736 - AstraZeneca
  • Abemaciclib - Eli Lilly and Company
  • Others 

Major regions analyzed under this research report are:

  • Europe
  • North America
  • Asia Pacific
  • Rest of the World 

This report gives you access to decisive data such as:

  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for the coming years 

Key highlights of this report

  • Overview of key market forces propelling and restraining market growth
  • Up-to-date analyses of market trends and technological improvements
  • Pin-point analyses of market competition dynamics to offer you a competitive edge
  • An analysis of strategies of major competitors
  • An array of graphics and SWOT analysis of major industry segments
  • Detailed analyses of industry trends
  • A well-defined technological growth map with an impact-analysis
  • Offers a clear understanding of the competitive landscape and key product segments 

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Non Small Cell Lung Cancer Market

Buy Now